Month: September 2020

We have been following gold in The War Room since our inception in May 2019. And since that time, members have taken dozens of winners ranging from junior miners to leveraged ETFs.
The key to trading gold and gold shares right now is to buy on dips. Precious metals are in the middle of a confirmed bull market, outperforming every other major asset class in 2020.
That trend should continue, and you should position yourself to be a buyer on dips.
In The War Room, we are constantly trading metals stocks but always making sure at least one position is in the portfolio …read more […]

Despite a global pandemic and some ugly economic forecasts, three industries have managed to buck the trend, and they’re only just getting started …read more […]

In 1966, Peter Lynch began as an intern with Fidelity Investments.
He got his foot in the door because he caddied at Brae Burn Country Club in West Newton, Massachusetts, for Fidelity’s president at the time, George Sullivan.
After returning from a two-year stint in the U.S. Army in 1969, Lynch got on full time with Fidelity. He started as an analyst following textiles, mining and chemicals.
From the beginning, it was apparent that Lynch was a gifted investor. Within five years, he advanced to become Fidelity’s director of research.
Then, in 1977, he got his big break…
Lynch was put in charge of a …read more […]

The post How to Avoid Investing Self-Sabotage appeared first on Investment U. …read more […]

Stock futures opened slightly higher Thursday evening after another volatile session earlier in the day sent the three major indices tumbling anew. …read more […]

Peloton will be getting into the used bike business very soon. …read more […]

Business is business, and business waits for no man – or virus. Even during the corona crisis, companies were conducting IPOs, moving from the fully private sector to the public trading sphere. And Wall Street’s best analysts have wasted no time getting the word out on which of these companies are worth an investor’s second look – and which are too risky.Making stock selections from the recent IPOs can take a little more homework than investors may be used to. The established companies have a history and a track record that can guide investors. The newer IPOs have yet to …read more […]

James Hardiman, Wedbush Securities Leisure & Travel Analyst, joined The Final Round to discuss Peloton’s fourth quarter earnings and his outlook for the stock as more people look to buy equipment to workout at home. …read more […]

Yahoo Finance’s Kristin Myers and Dan Howley discuss why DraftKings is skyrocketing as Penn National gets a ‘buy’ rating from Rosenblatt. …read more […]

Fitness giant Peloton has been a stock to watch as at-home fitness surges in popularity due to COVID-19. Yahoo Finance’s Myles Udland breaks down the company’s fourth-quarter earnings report on The Final Round. …read more […]

Oracle also said it won a deal with business software firm Xactly in which Xactly will move the majority of its computing work to Oracle’s cloud service. Oracle has been working to catch larger cloud rivals such as Amazon.com’s Amazon Web Services or Microsoft Corp’s Azure. …read more […]

Oracle Corporation released its first quarter earnings report after hours on Thursday, beating expectations on both top and bottom lines. The company’s CEO said the earnings were ‘fantastic’ and that they were confident their ‘revenue would accelerate’ past the coronavirus pandemic. Yahoo Finance’s Jared Blikre breaks down the company’s earnings report on The Final Round. …read more […]

Peloton reported fiscal fourth-quarter earnings after the bell Thursday. …read more […]

The recent news of an adverse reaction suffered by a participant in AstraZeneca’s Covid-19 vaccine candidate’s clinical trial demonstrated that getting an approved vaccine to market is no straight forward matter. What the unfortunate event also shows, is that the race to be first across the finish line with a viable solution is far from over.The field is still open, then, for vaccine specialist Vaxart (VXRT) to make its mark. The small cap is still far behind other major players in the development of its COVID-19 vaccine program, but following the publication of promising pre-clinical trial data, B Riley FBR …read more […]

NEW YORK, Sept. 10, 2020 /CNW/ — LAVVAN, Inc. …read more […]